FMP
Amylyx Pharmaceuticals, Inc.
AMLX
NASDAQ
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
4.05 USD
0.09 (2.22%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
CIK
0001658551
ISIN
US03237H1014
CUSIP
03237H101
Address
43 Thorndike Street
Phone
617 682 0917
Country
US
Employee
384
IPO Date
Jan 7, 2022
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
AMLX Financial Summary
CIK
0001658551
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
03237H101
ISIN
US03237H1014
Country
US
Price
4.05
Beta
-0.7
Volume Avg.
1.37M
Market Cap
277.62M
Shares
-
52-Week
1.575-19.949
DCF
-14.63
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.06
P/B
-
Website
https://amylyx.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest AMLX News
It looks like there's no news available.
